Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Mesoblast LimitedNASDAQ: MESO

Net Income · Q4 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q4 FY2026 net income of $8.67M (cash outflow) fell 68.0% year over year, ahead of the -91.5% change in trailing-twelve-month net income.

Context

  • Net income amounted to 0.0% of revenue in FY2026, down 593.9 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -68.0% holds above the trailing-twelve-month pace of -91.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$8.67M— QoQ
Last fiscal yearJun 2026
$0+100.0% YoY
LTMJun 2026
-$8.67M-91.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-68.0%——
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Income history

USD · from the cash flow

Latest · FY2026
0 USD
Year-over-year change
+100.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 net income of $8.67M is the 5th largest of the 6 companies compared; the peer median is $91.72M.
  • Its year-over-year change of -91.5% is the 5th highest of 6, against a peer median of +58.4%.
  • Net income amounts to 7.2% of revenue for MESO, versus a peer median of 389.3%.
MESO Competitors Peer median
Net Income for MESO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$80.71B +146477.0%+53.5%—
FATEFate Therapeutics, Inc.LTM Mar 2026$129.91M -26.1%-21.5%2056.8%
CELUCelularity Inc.LTM Dec 2025$91.72M +58.4%—345.4%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$64.01M +294.9%+34.1%433.1%
MESOMesoblast LimitedLTM Jun 2026$8.67M -91.5%—7.2%
LEGNLegend Biotech CorporationLTM Sep 2026$2.81M -98.7%-12.6%0.2%
Peer median (excluding MESO) $91.72M+58.4%+10.7%389.3%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income(91.35M)(81.89M)(87.96M)(102.14M)0
Depreciation & Amortization4.38M4.11M4.67M6.4M0
Deferred Income Tax(235K)(212K)(191K)330K0
Stock-Based Compensation5.54M3.66M5.87M22.09M0
Change in Working Capital4.87M(2.47M)(2.63M)(3.04M)0
Accounts Receivables140K(118K)(15.47M)6.29M0
Inventory000826K0
Accounts Payables00000
Other Working Capital4.73M(2.35M)12.84M(10.16M)0
Other Non-Cash Items11.02M13.54M31.78M26.41M(43.83M)
Operating Cash Flow(65.78M)(63.27M)(48.46M)(49.95M)(43.83M)
Capital Expenditures(232K)(314K)(331K)(730K)(898K)
Acquisitions (Net)00000
Purchases of Investments0000(125K)
Sales of Investments0120K234K241K0
Other Investing Activities(75K)120K(60K)559K(65K)
Investing Cash Flow(232K)(194K)(97K)120K(1.02M)
Debt Repayment(6.33M)(2.66M)(13.52M)(9.77M)(5.94M)
Common Stock Issued209K88.64M65.41M161.21M14.24M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.75M)(11.48M)(11.63M)(4.1M)(23.64M)
Financing Cash Flow(9.87M)74.5M40.25M147.34M(15.33M)
Effect of Forex Changes(550K)(168K)(55K)1.09M1.55M
Net Change in Cash(76.43M)10.87M(8.36M)98.59M(58.64M)
Free Cash Flow(66.01M)(63.58M)(48.79M)(50.68M)(44.73M)

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.